- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02430688
Irreversible Electroporation(IRE) For Unresectable Extremities Neoplasms (IRE)
September 1, 2021 updated by: Fuda Cancer Hospital, Guangzhou
Irreversible Electroporation(IRE) For Unresectable Extremities Neoplasms: Phase I and Phase II Clinical Trial
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Extremities Neoplasms.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
By enrolling patients with unresectable Extremites Neoplasms adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous IRE for unresectable Extremities Neoplasms.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Biological treatment center in Fuda cancer hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Extremities Neoplasms diagnosed by positive biopsy or non-invasive criteria,
- Not suitable for surgical resection,
- Eastern Cooperative Oncology Group (ECOG) score of 0-1,
- A prothrombin time ratio > 50%,
- Platelet count > 80x10^9/L,
- Ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post NanoKnife procedure,
- Able to comprehend and willing to sign the written informed consent form (ICF),
- Have a life expectancy of at least 3 months.
Exclusion Criteria:
- Cardiac insufficiency, ongoing coronary artery disease or arrhythmia,
- Any active implanted device (eg Pacemaker),
- Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,
- Have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System,
- Are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
The patients without treatment
|
|
Experimental: IRE Group
irreversible electroporation for Unresectable Extremities Neoplasms
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with Adverse events
Time Frame: 6 month
|
6 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of lesions that show no sign of recurrence 12 months after IRE
Time Frame: 12 months
|
12 months
|
|
Progress free disease (PFS)
Time Frame: 12 months
|
12 months
|
|
Overall survival (OS)
Time Frame: 36 months
|
Patients will be followed for 36 months after IRE for OS analyzed.
|
36 months
|
A minimum and maximum range of voltage for safe and effective IRE
Time Frame: 3 months
|
A minimum and maximum range of voltage for safe and effective IRE will be
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2015
Primary Completion (Actual)
December 1, 2020
Study Completion (Actual)
February 1, 2021
Study Registration Dates
First Submitted
April 26, 2015
First Submitted That Met QC Criteria
April 29, 2015
First Posted (Estimate)
April 30, 2015
Study Record Updates
Last Update Posted (Actual)
September 5, 2021
Last Update Submitted That Met QC Criteria
September 1, 2021
Last Verified
April 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Extremities Neoplasms -IRE-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Extremities Neoplasms
-
M.D. Anderson Cancer CenterRecruitingStage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8United States
-
University of WashingtonExelixisActive, not recruitingStage I Soft Tissue Sarcoma of the Trunk and Extremities | Stage II Soft Tissue Sarcoma of the Trunk and Extremities | Sarcoma of the Extremity | Stage IA Soft Tissue Sarcoma of the Trunk and Extremities | Stage IB Soft Tissue Sarcoma of the Trunk and ExtremitiesUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingSoft Tissue Sarcoma | Stage I Soft Tissue Sarcoma of the Trunk and Extremities | Stage II Soft Tissue Sarcoma of the Trunk and Extremities | Stage III Soft Tissue Sarcoma of the Trunk and ExtremitiesUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingStage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Resectable Soft Tissue Sarcoma | Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IB Soft Tissue Sarcoma of the Trunk and Extremities...United States
-
Hôpital Européen MarseilleAix Marseille UniversitéTerminatedVasoconstriction Disorder of ExtremitiesFrance
-
Maastricht University Medical CenterNot yet recruitingTypes of C-arm Procedures Included | Low Complex (Lower & Upper Extremities) | High Complex (Lower Extremities & Spinal Cord)
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Resectable... and other conditionsUnited States
-
Indonesia UniversityCompletedLower Extremities FractureIndonesia
-
Abramson Cancer Center of the University of PennsylvaniaTerminatedSoft Tissue Sarcoma of the ExtremitiesUnited States
-
ReFlow Medical, Inc.CompletedChronic Total Occlusion of Artery of the ExtremitiesUnited States
Clinical Trials on NanoKnife
-
Fuda Cancer Hospital, GuangzhouCompleted
-
Fuda Cancer Hospital, GuangzhouCompleted
-
Clinical Research Office of the Endourological...Active, not recruiting
-
Amsterdam UMC, location VUmcCompletedPancreatic Cancer | Locally Advanced Pancreatic Carcinoma (LAPC) | Non-metastasized Unresectable Pancreatic CarcinomaNetherlands
-
Angiodynamics, Inc.Active, not recruitingProstate CancerUnited States
-
Methodist Health SystemRecruiting
-
National Taiwan University HospitalCompletedMalignant Liver TumorsTaiwan
-
Clinical Research Office of the Endourological...Angiodynamics, Inc.CompletedProstate CancerNetherlands
-
Fuda Cancer Hospital, GuangzhouCompletedHilus Pulmonary NeoplasmsChina
-
Fuda Cancer Hospital, GuangzhouCompletedUterine Cervical NeoplasmsChina